FibroGen (FGEN) Tops Q3 EPS by 3c

Go back to FibroGen (FGEN) Tops Q3 EPS by 3c

FibroGen Reports Third Quarter 2023 Financial Results

November 6, 2023 4:01 PM EST

Topline data from two pivotal pamrevlumab pancreatic cancer trials on track to read out in 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic cancer Third quarter net revenue of $40.1 million, an increase of 155% year over year Roxadustat sNDA accepted in China for chemotherapy-induced anemia... More